IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CARLO STELLA, CARMELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.540
NA - Nord America 6.975
AS - Asia 6.045
SA - Sud America 749
AF - Africa 171
OC - Oceania 66
Continente sconosciuto - Info sul continente non disponibili 3
Totale 22.549
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.735
GB - Regno Unito 2.855
CN - Cina 2.019
IT - Italia 1.651
SG - Singapore 1.578
DE - Germania 1.018
SE - Svezia 816
RU - Federazione Russa 666
HK - Hong Kong 493
BR - Brasile 475
VN - Vietnam 335
IN - India 304
TR - Turchia 284
FR - Francia 282
UA - Ucraina 278
BD - Bangladesh 272
IE - Irlanda 203
KR - Corea 186
JP - Giappone 185
NL - Olanda 181
FI - Finlandia 160
CA - Canada 138
ES - Italia 133
AR - Argentina 103
EU - Europa 83
CO - Colombia 76
ID - Indonesia 64
MX - Messico 63
PL - Polonia 49
TH - Thailandia 47
AU - Australia 45
BE - Belgio 41
TW - Taiwan 38
ZA - Sudafrica 34
CI - Costa d'Avorio 31
IQ - Iraq 29
CH - Svizzera 28
CZ - Repubblica Ceca 27
EG - Egitto 27
IL - Israele 27
PK - Pakistan 23
SA - Arabia Saudita 23
DK - Danimarca 22
GR - Grecia 21
CL - Cile 20
JO - Giordania 20
NZ - Nuova Zelanda 20
AT - Austria 19
MA - Marocco 19
RO - Romania 19
EC - Ecuador 18
IR - Iran 16
KE - Kenya 16
PE - Perù 16
VE - Venezuela 15
UZ - Uzbekistan 14
PH - Filippine 13
PT - Portogallo 13
LB - Libano 12
MY - Malesia 12
UY - Uruguay 12
HR - Croazia 11
TN - Tunisia 10
BG - Bulgaria 9
AZ - Azerbaigian 8
DZ - Algeria 8
ET - Etiopia 8
JM - Giamaica 8
PY - Paraguay 8
SK - Slovacchia (Repubblica Slovacca) 8
NP - Nepal 7
AE - Emirati Arabi Uniti 6
BO - Bolivia 6
CR - Costa Rica 6
NG - Nigeria 6
SI - Slovenia 6
GT - Guatemala 5
NO - Norvegia 5
PA - Panama 4
PS - Palestinian Territory 4
AL - Albania 3
BB - Barbados 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
KZ - Kazakistan 3
LK - Sri Lanka 3
LT - Lituania 3
OM - Oman 3
RS - Serbia 3
AM - Armenia 2
BY - Bielorussia 2
CY - Cipro 2
GH - Ghana 2
HN - Honduras 2
KG - Kirghizistan 2
MD - Moldavia 2
MN - Mongolia 2
QA - Qatar 2
TT - Trinidad e Tobago 2
YT - Mayotte 2
Totale 22.604
Salva come PNG Salva come JPEG
Città #
Southend 2.563
Singapore 861
Ashburn 664
Frankfurt am Main 529
Milan 516
Seattle 456
Hong Kong 451
Chandler 414
Beijing 349
Wilmington 324
San Jose 294
Princeton 261
Fairfield 220
Dallas 214
Jacksonville 214
Dublin 199
Council Bluffs 182
Nanjing 150
Woodbridge 150
Redwood City 148
Los Angeles 147
Houston 139
Santa Clara 133
Guangzhou 129
Ann Arbor 124
Bengaluru 124
New York 123
Shanghai 115
Dearborn 108
Lauterbourg 107
Redmond 103
Moscow 102
Hanoi 96
Ho Chi Minh City 94
Columbus 92
Mountain View 89
Des Moines 88
Serra 88
Buffalo 83
Hefei 81
Cambridge 78
Rome 74
Somerville 68
Sakarya 67
Tokyo 67
Tianjin 63
Boardman 62
Hangzhou 60
Bogotá 57
Phoenix 54
São Paulo 51
The Dalles 50
Andover 47
Brescia 46
Istanbul 45
Jakarta 41
Nanchang 40
Jinan 39
Shenyang 36
Munich 35
Toronto 33
Buenos Aires 32
Chicago 31
Seoul 31
Abidjan 30
Cangzhou 29
Helsinki 29
Madrid 29
Brussels 26
Hebei 26
Shenzhen 26
Changsha 25
London 25
Bologna 24
Hanover 24
Pisa 24
Washington 24
Bangkok 23
Falls Church 23
San Diego 23
Berlin 22
Nuremberg 22
Sydney 22
Taipei 22
Atlanta 21
Philadelphia 21
Jiaxing 20
Kunming 20
Wuhan 20
Florence 19
Québec 19
Zhengzhou 19
Ankara 18
Turin 18
Cairo 17
Chengdu 17
Mumbai 17
Rio de Janeiro 17
Auburn Hills 16
Fuzhou 16
Totale 13.324
Salva come PNG Salva come JPEG
Nome #
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma : Final results of a multicenter phase II study 2.232
FGF trapping inhibits multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress 763
Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside 671
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 419
Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies : posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery 323
Italian real life experience with brentuximab vedotin : results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma 288
Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection 276
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells 264
Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia 253
Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma 247
Role of naïve-derived T memory stem cells in T cell reconstitution following allogeneic transplantation 245
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide 242
Targeting TRAIL Receptors with Genetically-Engineered CD34+ Hematopoietic Stem Cells 236
Ex vivo expansion of hematopoietic cells and their clinical use 234
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion : an outpatient preparative regimen for autologous hematopoietic cell transplantation 232
Interferon γ enhances the anti-myeloma activity of the fully human anti-HLA-DR monoclonal antibody 1D09C3 228
Amifostine (WR-2721) selective protection against melphalan genotoxicity 225
D Quantification of Tumor Vasculature in Lymphoma Xenografts in NOD/SCID Mice Allows to Detect Differences among Vascular-Targeted Therapies 218
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a phase I trial in metastatic melanoma 218
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 216
The anti-HLA-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing NOD/SCID mice 215
Forced Expression of RDH10 Gene Retards Growth of HepG2 Cells 213
Human CD34+ cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature 211
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers 209
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH) 209
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34+ cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial 208
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (mTRAIL) 207
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts 202
Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed 195
Skewed T cell differentiation in indolent non-Hodgkin's lymphoma patients reversed by ex-vivo T cell culture with {gamma}c-cytokines 194
Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Agonistic Receptors for Cancer Therapy 193
Anticancer cell therapy with TRAIL-armed CD34+ progenitor cells 193
Synergistic in vitro effect of Second Mitochondria-derived Activator of Caspases mimetic compounds (Smac) and Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on human acute leukemia cell lines 192
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis 190
High-dose sequential chemotherapy and in vivo Rituximab-purged stem cell autografting in mantle cell lymphoma : a 10-year update of the R-HDS regimen 190
B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY 188
Second mitochondria-derived activator of caspases mimetic compounds (Smac) enhance tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) pro-Apoptotic effect on human myeloid leukemia cell lines 185
Effect of Second Mitochondria-Derived Activator of Caspases (Smac) Mimetic Compounds on Leukemic Cell Lines 185
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis 185
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®) 185
Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes 184
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments 184
Antitumor activity of adenovirally transduced CD34+ cells expressing membrane-bound TRAIL 183
New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia 183
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor : an algorithm for the pre-emptive use of plerixafor 183
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation 183
Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma 182
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors : mature results of an Italian randomized phase II study 182
Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts 179
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma 178
Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients 177
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases 177
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) 176
Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with Defibrotide and recombinant human granulocyte colony-stimulating factor 176
Fattori di crescita emopoietici in oncologia 175
Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies 175
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts 172
Placental Growth Factor-1 Potentiates Hematopoietic Progenitor Cell Mobilization Induced by Granulocyte Colony-Stimulating Factor in Mice and Nonhuman Primates 171
Biology and clinical applications of marrow mesenchymal stem cells 171
Highly efficient gene transfer into mobilized CD34+ hematopoietic cells using serotype-5 adenoviral vectors and BoosterExpress™ Reagent 168
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells 168
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF 166
Methodological framework for radiomics applications in Hodgkin’s lymphoma 166
Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene 160
La sfida estrema : la plasticità delle cellule staminali 160
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation : results from a named patient program at four Italian centers 159
High response rate and manageable toxicity with an intensive, short-term chemotherapy program for Burkitt’s lymphoma in adults 157
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B-cell lymphoma patients with relapsed and measurable disease : a pilot study 156
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation 155
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells 153
Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders 153
Cellule staminali emopoietiche 150
Section Editor per Ematologia Sperimentale di Annals of Hematology 147
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 147
Detection of minimal residual disease in hematopoietic progenitor cell harvests : lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma 146
Trapianto di cellule staminali mesenchimali : razionale e prospettive 144
Membro del Comitato Editoriale di Stem cells 141
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells 139
Radioimmunotherapy and secondary leukemia : a case report 138
Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells 138
Long-term lymphoma survivors following high-dose chemotherapy and autograft : evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir 136
Membro del Comitato Editoriale di Recent patents on anti-cancer drug discovery 135
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli 135
Bone Marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide 133
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia : evidence for premature aging of the myeloid compartment 130
Counterflow centrifugal elutriation: present and future 128
Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor 127
Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma : long-term follow-up 126
Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes 124
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis 124
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target 120
The role of inflammation in lymphoma 117
Comparative assessment of telomere length before and after hematopoietic SCT : role of grafted cells in determining post-transplant telomere status 116
Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts 116
Long-term results of autologous hematopoietic stem-cell transplantation after high-dose 90Y-ibritumomab tiuxetan for patients with poor-risk non-Hodgkin lymphoma not eligible for high-dose BEAM 116
Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi 115
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma : a single institution experience 113
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death 113
The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide 112
Membro del Comitato Editoriale di Current stem cell research & therapy 111
Totale 21.028
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.565
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.565
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021108 0 0 0 0 0 0 0 0 0 0 0 108
2021/20221.576 185 77 74 118 88 122 118 95 112 152 108 327
2022/20231.905 247 190 150 201 205 364 78 132 167 34 83 54
2023/20241.520 54 113 94 88 291 86 126 115 63 95 166 229
2024/20252.904 176 330 97 296 164 96 123 328 198 207 274 615
2025/20265.594 548 325 593 483 551 433 577 389 618 334 469 274
Totale 23.608